Oncosence B.V., is a joint spin-off company of the Institute of Oncology Research (IOR) in Bellinzona and the Oncode Institute, Netherlands. Oncosence has been incorporated in 2018. Andrea Alimonti, Professor at the Università della Svizzera italiana (USI), is a cofounder of Oncosence and one of the inventors of the patent licensed to the company. The invention, developed at the institute affiliated to the University, relates to methods for treatment of cancer by inducing senescence in cancer cells. Oncosence works with an approach that selectively enhances the ageing process in cancer cells, and specifically targets them to prevent tumor progression. This so called “two-punch” approach stops cancer growth by driving cancer cells into an ageing state and consecutively clears cancer cells in that state.


Oncosence - homepage